Search

EHA-Balkan Hematology Day 2025

The EHA-Balkan Hematology Day is a two-day meeting jointly organized by the European Hematology Association, the Macedonian Hematology Association, and the Macedonian Academy of Sciences and Arts.

Read more

Grants & abstract awards

EHA Travel GrantsThe call for travel grant applications closed on March 1, 2025 (23:59 CET). The grants will only be available for investigators with accepted abstracts, submitted during the regular abstract submission.

Read more

Abstract submission

Abstract procedureThe official abstract submission closed on March 1, 2025 (23:59 CET).

Read more

Late-Breaking Abstract Submission

Late-breaking abstract procedureThe official late-breaking abstract submission will open from May 2 to 9, 2025 (09:00 CEST). The full late-breaking abstract submission terms & conditions can be found here.

Read more

Selected EMA news

March 2025New medicines recommended for approval
Lynozyfic (linvoseltamab) 
Treatment of refractory multiple myeloma (a cancer of the bone marrow)
New information on approved medicines 
Calquence (acalabrutinib) - new indication
Treatment of blood cancer

Columvi (glofitamab) - new indication
Treatment of blood cancer

Darzalex (daratumumab) - change of indication
Treatment…

Read more

Fellowships and Grants Committee call for interest

The Fellowships and Grants Committee is responsible for assigning EHA funding to talented researchers. This year, we are looking for two new committee members.

Read more

Community and Stakeholder Committee call for interest

The Community and Stakeholder Committee (CSC) serves as an advisory body to the EHA Board and works closely with the EHA Office and other committees.

Read more

Guidelines Committee call for interest

The aim of the Guidelines Committee is to promote and support the creation and adoption of guidelines for diagnosis and treatment of hematologic diseases.

Read more

Research Committee call for interest

The overarching aim of the Research Committee is to further strengthen EHA’s interactions with and relevance for the wider hematological research community.

Read more